NASDAQ:RLAY
Relay Therapeutics, Inc.
Relay Therapeutics, Inc.'s revenue grew 53.4% in fiscal 2025 to $15.4M while operating margin rose to −1971.6%. Free cash flow was −$235.9M, −1536.1% of revenue.Summary generated from Relay Therapeutics, Inc.'s SEC filings. Latest annual report filed Feb 26, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$15.4M
Revenue growth+53.4%
Revenue, 5-yr CAGR−28.6%
Gross marginn/a
Operating margin−1971.6%
Net margin−1800.6%
ROICn/a
Return on equity−41.1%
Debt / equityn/a
Free cash flow−$235.9M
FCF margin−1536.1%
Share count changen/a
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 3 | 1 | 26 | 10 | 15 |
| Operating income | −365 | −299 | −373 | −372 | −303 |
| Net income | −364 | −291 | −342 | −338 | −276 |
| Free cash flow | −78 | −239 | −304 | −251 | −236 |
Recent filings
- 4Insider transaction report
Oct 8, 2026 - 4Insider transaction report
Oct 8, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 6, 2026 - 8-KEntry into a material agreement
Aug 6, 2026 - 8-KAmendment to articles or bylaws
Jun 9, 2026 - 8-KEntry into a material agreement
May 21, 2026 - 8-KRegulation FD disclosure
May 19, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 5, 2026